Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin's lymphoma patients

M. Benekli, T. Hahn, F. Shafi, A. Qureshi, A. R. Alam, M. S. Czuczman, Z. P. Bernstein, Asher A Chanan Khan, J. L. Becker, P. L. McCarthy

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Rituximab is used for in vivo tumor cell purging for non-Hodgkin's lymphoma (NHL) patients prior to autologous peripheral blood stem cell transplantation (PBSCT). However, its effects on PBSC mobilization and function are poorly understood. We compared the mobilization characteristics and engraftment kinetics of 13 NHL patients receiving and 34 NHL patients not receiving rituximab 6 months before PBSC mobilization. In the rituximab group, there was a significantly longer time to neutrophil engraftment (P = 0.0466), a trend toward the need for BM harvest to supplement low-yield PBSC collections (31 vs 9%, P = 0.08) and a significantly increased rate of bacteremia episodes (62 vs 26%, P = 0.025). Median progression-free survival (PFS) and overall survival (OS) were significantly longer in the rituximab compared to the nonrituximab patients (P = 0.049 and 0.042, respectively). However, patients in the nonrituximab group were at high risk for recurrence and expected to have shorter survival. Rituximab used within 6 months prior to collection may have a detrimental effect on PBSC mobilization and engraftment. However, rituximab is a major therapeutic breakthrough for NHL treatment and this negative effect may be offset by improved survival. Further studies are warranted in larger populations to determine the impact of rituximab on engraftment, PFS and OS.

Original languageEnglish (US)
Pages (from-to)139-143
Number of pages5
JournalBone Marrow Transplantation
Volume32
Issue number2
DOIs
StatePublished - Jul 2003
Externally publishedYes

Fingerprint

Hematopoietic Stem Cell Mobilization
Non-Hodgkin's Lymphoma
Survival
Disease-Free Survival
Peripheral Blood Stem Cell Transplantation
Bacteremia
Peripheral Blood Stem Cells
Rituximab
Neutrophils
Recurrence
Therapeutics

Keywords

  • Non-Hodgkin's lymphoma
  • Rituximab
  • Stem cell mobilization

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Benekli, M., Hahn, T., Shafi, F., Qureshi, A., Alam, A. R., Czuczman, M. S., ... McCarthy, P. L. (2003). Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin's lymphoma patients. Bone Marrow Transplantation, 32(2), 139-143. https://doi.org/10.1038/sj.bmt.1704106

Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin's lymphoma patients. / Benekli, M.; Hahn, T.; Shafi, F.; Qureshi, A.; Alam, A. R.; Czuczman, M. S.; Bernstein, Z. P.; Chanan Khan, Asher A; Becker, J. L.; McCarthy, P. L.

In: Bone Marrow Transplantation, Vol. 32, No. 2, 07.2003, p. 139-143.

Research output: Contribution to journalArticle

Benekli, M, Hahn, T, Shafi, F, Qureshi, A, Alam, AR, Czuczman, MS, Bernstein, ZP, Chanan Khan, AA, Becker, JL & McCarthy, PL 2003, 'Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin's lymphoma patients', Bone Marrow Transplantation, vol. 32, no. 2, pp. 139-143. https://doi.org/10.1038/sj.bmt.1704106
Benekli, M. ; Hahn, T. ; Shafi, F. ; Qureshi, A. ; Alam, A. R. ; Czuczman, M. S. ; Bernstein, Z. P. ; Chanan Khan, Asher A ; Becker, J. L. ; McCarthy, P. L. / Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin's lymphoma patients. In: Bone Marrow Transplantation. 2003 ; Vol. 32, No. 2. pp. 139-143.
@article{76f1ab1c332e4140a046854ded848f10,
title = "Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin's lymphoma patients",
abstract = "Rituximab is used for in vivo tumor cell purging for non-Hodgkin's lymphoma (NHL) patients prior to autologous peripheral blood stem cell transplantation (PBSCT). However, its effects on PBSC mobilization and function are poorly understood. We compared the mobilization characteristics and engraftment kinetics of 13 NHL patients receiving and 34 NHL patients not receiving rituximab 6 months before PBSC mobilization. In the rituximab group, there was a significantly longer time to neutrophil engraftment (P = 0.0466), a trend toward the need for BM harvest to supplement low-yield PBSC collections (31 vs 9{\%}, P = 0.08) and a significantly increased rate of bacteremia episodes (62 vs 26{\%}, P = 0.025). Median progression-free survival (PFS) and overall survival (OS) were significantly longer in the rituximab compared to the nonrituximab patients (P = 0.049 and 0.042, respectively). However, patients in the nonrituximab group were at high risk for recurrence and expected to have shorter survival. Rituximab used within 6 months prior to collection may have a detrimental effect on PBSC mobilization and engraftment. However, rituximab is a major therapeutic breakthrough for NHL treatment and this negative effect may be offset by improved survival. Further studies are warranted in larger populations to determine the impact of rituximab on engraftment, PFS and OS.",
keywords = "Non-Hodgkin's lymphoma, Rituximab, Stem cell mobilization",
author = "M. Benekli and T. Hahn and F. Shafi and A. Qureshi and Alam, {A. R.} and Czuczman, {M. S.} and Bernstein, {Z. P.} and {Chanan Khan}, {Asher A} and Becker, {J. L.} and McCarthy, {P. L.}",
year = "2003",
month = "7",
doi = "10.1038/sj.bmt.1704106",
language = "English (US)",
volume = "32",
pages = "139--143",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin's lymphoma patients

AU - Benekli, M.

AU - Hahn, T.

AU - Shafi, F.

AU - Qureshi, A.

AU - Alam, A. R.

AU - Czuczman, M. S.

AU - Bernstein, Z. P.

AU - Chanan Khan, Asher A

AU - Becker, J. L.

AU - McCarthy, P. L.

PY - 2003/7

Y1 - 2003/7

N2 - Rituximab is used for in vivo tumor cell purging for non-Hodgkin's lymphoma (NHL) patients prior to autologous peripheral blood stem cell transplantation (PBSCT). However, its effects on PBSC mobilization and function are poorly understood. We compared the mobilization characteristics and engraftment kinetics of 13 NHL patients receiving and 34 NHL patients not receiving rituximab 6 months before PBSC mobilization. In the rituximab group, there was a significantly longer time to neutrophil engraftment (P = 0.0466), a trend toward the need for BM harvest to supplement low-yield PBSC collections (31 vs 9%, P = 0.08) and a significantly increased rate of bacteremia episodes (62 vs 26%, P = 0.025). Median progression-free survival (PFS) and overall survival (OS) were significantly longer in the rituximab compared to the nonrituximab patients (P = 0.049 and 0.042, respectively). However, patients in the nonrituximab group were at high risk for recurrence and expected to have shorter survival. Rituximab used within 6 months prior to collection may have a detrimental effect on PBSC mobilization and engraftment. However, rituximab is a major therapeutic breakthrough for NHL treatment and this negative effect may be offset by improved survival. Further studies are warranted in larger populations to determine the impact of rituximab on engraftment, PFS and OS.

AB - Rituximab is used for in vivo tumor cell purging for non-Hodgkin's lymphoma (NHL) patients prior to autologous peripheral blood stem cell transplantation (PBSCT). However, its effects on PBSC mobilization and function are poorly understood. We compared the mobilization characteristics and engraftment kinetics of 13 NHL patients receiving and 34 NHL patients not receiving rituximab 6 months before PBSC mobilization. In the rituximab group, there was a significantly longer time to neutrophil engraftment (P = 0.0466), a trend toward the need for BM harvest to supplement low-yield PBSC collections (31 vs 9%, P = 0.08) and a significantly increased rate of bacteremia episodes (62 vs 26%, P = 0.025). Median progression-free survival (PFS) and overall survival (OS) were significantly longer in the rituximab compared to the nonrituximab patients (P = 0.049 and 0.042, respectively). However, patients in the nonrituximab group were at high risk for recurrence and expected to have shorter survival. Rituximab used within 6 months prior to collection may have a detrimental effect on PBSC mobilization and engraftment. However, rituximab is a major therapeutic breakthrough for NHL treatment and this negative effect may be offset by improved survival. Further studies are warranted in larger populations to determine the impact of rituximab on engraftment, PFS and OS.

KW - Non-Hodgkin's lymphoma

KW - Rituximab

KW - Stem cell mobilization

UR - http://www.scopus.com/inward/record.url?scp=10744221571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744221571&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1704106

DO - 10.1038/sj.bmt.1704106

M3 - Article

VL - 32

SP - 139

EP - 143

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 2

ER -